AstraZeneca Pharma India informs about disclosure

15 Apr 2025 Evaluate
AstraZeneca Pharma India has informed that AstraZeneca Pharma India had vide its letter dated November 21, 2023, informed the receipt of Marketing Authorisation dated November 17, 2023 for Olaparib film-coated tablets 100mg and 150mg (Lynparza) which was indicated in combination with Abiraterone and Prednisone or Prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer. Through this letter, informed that the Company has now surrendered the marketing authorisation of the above-mentioned indication of Olaparib (Lynparza) 100mg and 150mg. Also confirmed that since the date of receipt of Marketing authorisation for the said indications, November 17, 2023, till date, it has never marketed the said indication in India. the discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons. Further, informed that it continue to hold all other existing permissions for the said drug Olaparib in India.

The above information is a part of company’s filings submitted to BSE.

Astrazeneca Pharma I Share Price

8961.95 -106.05 (-1.17%)
24-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.50
Dr. Reddys Lab 1201.45
Cipla 1551.30
Lupin 2104.90
Zydus Lifesciences 879.85
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...